DK1748781T3 - Fremgangsmåder til behandling af blødningsforstyrrelser under anvendelse af sulfaterede polysaccharider - Google Patents

Fremgangsmåder til behandling af blødningsforstyrrelser under anvendelse af sulfaterede polysaccharider

Info

Publication number
DK1748781T3
DK1748781T3 DK05765950.0T DK05765950T DK1748781T3 DK 1748781 T3 DK1748781 T3 DK 1748781T3 DK 05765950 T DK05765950 T DK 05765950T DK 1748781 T3 DK1748781 T3 DK 1748781T3
Authority
DK
Denmark
Prior art keywords
methods
sulfated polysaccharides
bleeding disorders
treating bleeding
treating
Prior art date
Application number
DK05765950.0T
Other languages
English (en)
Inventor
Kirk W Johnson
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Application granted granted Critical
Publication of DK1748781T3 publication Critical patent/DK1748781T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK05765950.0T 2004-05-27 2005-05-27 Fremgangsmåder til behandling af blødningsforstyrrelser under anvendelse af sulfaterede polysaccharider DK1748781T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57484504P 2004-05-27 2004-05-27
PCT/US2005/018669 WO2005117912A1 (en) 2004-05-27 2005-05-27 Methods for treating bleeding disorders using sulfated polysaccharides

Publications (1)

Publication Number Publication Date
DK1748781T3 true DK1748781T3 (da) 2013-02-11

Family

ID=35462725

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05765950.0T DK1748781T3 (da) 2004-05-27 2005-05-27 Fremgangsmåder til behandling af blødningsforstyrrelser under anvendelse af sulfaterede polysaccharider

Country Status (16)

Country Link
US (4) US7767654B2 (da)
EP (2) EP1748781B1 (da)
JP (2) JP5232470B2 (da)
CN (2) CN1984664B (da)
AU (1) AU2005249465B2 (da)
BR (1) BRPI0511603A (da)
CA (1) CA2567495C (da)
CY (1) CY1113705T1 (da)
DK (1) DK1748781T3 (da)
ES (2) ES2399277T3 (da)
HK (2) HK1103624A1 (da)
PL (1) PL1748781T3 (da)
PT (1) PT1748781E (da)
RU (1) RU2347574C2 (da)
SI (1) SI1748781T1 (da)
WO (1) WO2005117912A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
EP1748781B1 (en) * 2004-05-27 2012-12-19 Baxter International Inc. Methods for treating bleeding disorders using sulfated polysaccharides
US20080107678A1 (en) * 2006-04-27 2008-05-08 Johnson Kirk W Method for treating thrombotic disorders using sulfated polysaccharides
CN101663326B (zh) * 2007-02-23 2013-03-20 巴克斯特国际公司 从海藻提取物中纯化岩藻依聚糖的工艺方法
US9956272B2 (en) * 2007-05-30 2018-05-01 Bio Products Laboratory Limited Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
WO2009061697A1 (en) * 2007-11-09 2009-05-14 The Board Of Trustees Of The University Of Illinois Anticoagulant antagonist and hemophilia procoagulant
JP5896742B2 (ja) * 2008-08-22 2016-03-30 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ 出血性障害を処置するための方法
CN102307600B (zh) * 2008-12-11 2015-11-25 巴克斯特国际公司 以纤维蛋白原和硫酸化多糖为基础的制剂
KR102165021B1 (ko) 2008-12-19 2020-10-14 박스알타 인코퍼레이티드 Tfpi 억제제 및 사용 방법
WO2011088267A1 (en) * 2010-01-14 2011-07-21 Baxter International Inc. Methods and compositions for treating bleeding disorders
JP5730983B2 (ja) 2010-03-19 2015-06-10 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｔｆｐｉ阻害剤および使用方法
WO2011131720A1 (en) * 2010-04-20 2011-10-27 Octapharma Ag New stabilizing agent for pharmaceutical proteins
CN103221061A (zh) 2010-10-06 2013-07-24 米迪缪尼有限公司 用于治疗止血障碍的因子ii以及纤维蛋白原
JP6157464B2 (ja) * 2011-07-19 2017-07-05 バクスアルタ ゲーエムベーハー 非抗凝固性硫酸化多糖の経口製剤を改善するための添加剤としての吸収促進剤
WO2013116366A1 (en) * 2012-01-30 2013-08-08 Baxter International Inc. Non-anticoagulant sulfated or sulfonated polysaccharides
EP2809330B1 (en) 2012-01-30 2019-06-12 Baxalta GmbH Non-anticoagulant sulfated or sulfonated synthetic polymers
SI2827883T1 (sl) 2012-03-21 2019-08-30 Baxalta GmbH Inhibitorji TFPI in postopki uporabe
RU2472495C1 (ru) * 2012-05-05 2013-01-20 Илья Николаевич Медведев Способ нормализации уровня альфа2-антиплазмина у свиноматок с бронхитом
EP2662083A1 (en) 2012-05-08 2013-11-13 CSL Behring GmbH Sugar compositions for treating hemophilia a and/or von willebrand disease
WO2014028382A1 (en) 2012-08-14 2014-02-20 Baxter International Inc. Methods and systems for screening compositions comprising non-anticoagulant sulfated polysaccharides
CN103610684B (zh) * 2013-11-07 2016-04-06 苏州大学 糖类在制备治疗血小板数量相关疾病的药物中的应用
AU2017321817B2 (en) * 2016-08-31 2022-12-15 Oji Holdings Corporation Production method for acidic xylooligosaccharide, and acidic xylooligosaccharide
JP6225321B1 (ja) * 2016-08-31 2017-11-08 王子ホールディングス株式会社 ポリ硫酸ペントサンの製造方法
JP6281659B1 (ja) 2017-02-28 2018-02-21 王子ホールディングス株式会社 ポリ硫酸ペントサン、医薬組成物及び抗凝固剤
SG11201911318SA (en) 2017-05-31 2020-01-30 Oji Holdings Corp Moisturizing topical preparation
WO2019054344A1 (ja) 2017-09-12 2019-03-21 王子ホールディングス株式会社 ポリ硫酸ペントサン及びポリ硫酸ペントサンの製造方法
CN111511773B (zh) 2017-12-20 2023-01-13 王子控股株式会社 戊聚糖多硫酸酯以及含有戊聚糖多硫酸酯的药物
CN108822231A (zh) * 2018-06-29 2018-11-16 桂林理工大学 一种具有提高抗氧化活性的果胶多糖硫酸化修饰产物及其制备方法
SE1950885A1 (en) * 2019-07-11 2021-01-12 Faelker Knut Treatment of patients undergoing antiplatelet medication experiencing acute bleeding complications during / after surgery

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79254A0 (en) * 1986-06-26 1986-09-30 Hadassah Med Org Compositions for preventing graft rejection
IL85145A (en) * 1987-01-23 1994-08-26 Univ Australian Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity
DE69108896T2 (de) * 1990-11-05 1995-08-24 Baxter Diagnostics Inc Verfahren zur bestimmung der konzentration von antikoagulantien.
JP3714426B2 (ja) 1994-02-01 2005-11-09 株式会社糖鎖工学研究所 フコイダンオリゴ糖組成物含有癌転移抑制剤
RU2193039C2 (ru) * 1995-04-28 2002-11-20 Такара Сузо Ко., Лтд. Соединение сахара
FR2754183A1 (fr) * 1996-10-08 1998-04-10 Lefebvre Jean Marie Composition visqueuse hemostatique, notamment a l'etat de gel
JP2002506515A (ja) * 1997-04-25 2002-02-26 ペンタファルム アクチェンゲゼルシャフト 蛋白質ｃ−系における障害の機能的検出法
UA65587C2 (en) * 1997-10-09 2004-04-15 Baker Norton Pharma Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus
CN1192780C (zh) * 1999-04-15 2005-03-16 宝生物工程株式会社 治疗剂
EP1279405A1 (en) * 2000-03-30 2003-01-29 Ajinomoto Co., Inc. Drugs retained in target tissue over long time
IL156842A0 (en) * 2001-02-05 2004-02-08 Novo Nordisk Healthcare Ag Combined use of factor vii polypeptides and factor ix polypeptides
US20030203845A1 (en) * 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
ATE286075T1 (de) * 2001-10-24 2005-01-15 Takara Bio Inc Sulfatiertes fucan oligosaccharid
JP3941036B2 (ja) * 2001-12-07 2007-07-04 サンスター株式会社 経口投与のためのリポソーム組成物
DE10309368A1 (de) * 2002-08-06 2004-02-26 Aventis Behring Gmbh Intellectual Property/Legal Pharmazeutische Zubereitung mit RNA als Cofaktor der Hämostase
IL152030A0 (en) * 2002-09-30 2003-05-29 Nvr Labs Ltd Neural & Vascular Cohesive biopolymers comprising sulfated polysaccharides and fibrillar proteins and use thereof for tissue repair
JP2004144580A (ja) * 2002-10-23 2004-05-20 Japan Clinical Laboratories Inc 血液凝固検査方法
US20050033029A1 (en) * 2003-06-30 2005-02-10 Jin Lu Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
EP1748781B1 (en) * 2004-05-27 2012-12-19 Baxter International Inc. Methods for treating bleeding disorders using sulfated polysaccharides
US20080107678A1 (en) * 2006-04-27 2008-05-08 Johnson Kirk W Method for treating thrombotic disorders using sulfated polysaccharides

Also Published As

Publication number Publication date
HK1142276A1 (en) 2010-12-03
EP1748781A1 (en) 2007-02-07
HK1103624A1 (en) 2007-12-28
EP1748781A4 (en) 2008-07-02
PL1748781T3 (pl) 2013-05-31
EP2165711B1 (en) 2014-05-21
RU2006146801A (ru) 2008-07-10
AU2005249465A1 (en) 2005-12-15
ES2399277T3 (es) 2013-03-27
CN103251647A (zh) 2013-08-21
US7829549B2 (en) 2010-11-09
CY1113705T1 (el) 2016-06-22
US20050282771A1 (en) 2005-12-22
BRPI0511603A (pt) 2008-01-02
SI1748781T1 (sl) 2013-03-29
CN1984664A (zh) 2007-06-20
CA2567495A1 (en) 2005-12-15
US7767654B2 (en) 2010-08-03
JP5232470B2 (ja) 2013-07-10
RU2347574C2 (ru) 2009-02-27
CN1984664B (zh) 2013-07-24
EP2165711A1 (en) 2010-03-24
US8859526B2 (en) 2014-10-14
US20110237512A1 (en) 2011-09-29
JP2012046551A (ja) 2012-03-08
ES2482105T3 (es) 2014-08-01
AU2005249465B2 (en) 2007-12-06
CA2567495C (en) 2014-02-18
US20090269325A1 (en) 2009-10-29
JP2008500367A (ja) 2008-01-10
WO2005117912A1 (en) 2005-12-15
EP1748781B1 (en) 2012-12-19
US20120129777A1 (en) 2012-05-24
PT1748781E (pt) 2013-01-22
US8771973B2 (en) 2014-07-08

Similar Documents

Publication Publication Date Title
DK1748781T3 (da) Fremgangsmåder til behandling af blødningsforstyrrelser under anvendelse af sulfaterede polysaccharider
DK1827441T3 (da) Kombinationer til behandling af sygdomme, som involverer celleproliferation
SMAP200700009A (it) Succedaneo funzionale dello zucchero
DK1928882T3 (da) (s)-n-methylnaltrexon
DE602005000414D1 (de) Scheinwerfer
FR2873973B1 (fr) Lave-phare
NO20050605D0 (no) Ski
DE602005016309D1 (de) Laas-bodeneinrichtungs-sigma-monitor
DK1814555T3 (da) S-mirtazapin til behandling af hedeture
AT9812U2 (de) Schneegleitbrett
DK1955066T3 (da) Membran-assay-fremgangsmåde
FIU20060462U0 (fi) Pehmuste
ITRE20050028U1 (it) Spaccalegna perfezionato
ITRE20050027U1 (it) Spaccalegna perfezionato
AT7659U3 (de) Ski
ES1060996Y (es) Dispositivo de simulacion estetica.
SE0400209D0 (sv) Novel methods
UA11331S (uk) Дитяча гойдалка
FI20041315A0 (fi) Prosessi
ITMO20050232A1 (it) Metodo
FI20051209A (fi) Yläpuolelta pinnan alle painattava vaappu
FIU20050108U0 (fi) Halkaisulaite
FR2865942B1 (fr) Ski
FI20040274A0 (fi) Kuivaprosessijärjestelmä
FI20041569A0 (fi) Rakennuselementtijärjestelmä